Sun Pharmaceutical Industries has reported results for first quarter ended June 30, 2016.
The company has reported net loss at Rs 151.46 crore for the quarter as compared to net loss of Rs 396.35 crore for the same quarter in the previous year. Total income of the company decreased by 9.46% at Rs 1904.70 crore for quarter under review as compared to Rs 2103.67 crore for the quarter ended June 30, 2015.
On the consolidated basis, the company has reported over three fold jump in its net profit after taxes, minority interest share of profit of associates and joint ventures at Rs 2033.71 crore for the quarter ended June 30, 2016 as compared to Rs 555.90 crore for the same quarter in the previous year. However, total Income of the company increased by 21.29% to Rs 8400.09 crore for quarter under review from Rs 6925.60 crore for the quarter ended June 30, 2015.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1282.15 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2249.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: